Arbutus Biopharma Reports $10.74M Q2 Revenue, Improves Financials Amid Ongoing Legal Challenges

Arbutus Biopharma Corporation (NASDAQ: ABUS) has reported significant changes in its financial condition for the second quarter and first half of the year 2025. The company operates in the biopharmaceutical sector, focusing on the development of treatments for chronic hepatitis B (cHBV).

Positive Aspects:

• Revenue Growth: Total revenue surged to $10.74 million for Q2 2025, a substantial increase from $1.73 million in Q2 2024, mostly attributed to recognizing $9.6 million of previously deferred revenue related to the conclusion of its partnership with Qilu Pharmaceutical.
• Operational Efficiency: Total operating expenses decreased to $9.25 million in Q2 2025 from $23.31 million in Q2 2024, reflecting a shift towards a streamlined operation.
• Net Income: The company reported a net income of $2.52 million for Q2 2025, a stark contrast to a net loss of $19.80 million in the same quarter last year.

Negative Aspects:

• Declining Royalties: License royalty revenues, particularly from ONPATTRO and Acuitas Therapeutics, decreased due to lower sales in 2025 compared to previous periods.
• Increased Costs: Restructuring costs amounted to $12.54 million due to workforce reductions and exiting the company's Warminster headquarters, representing a significant one-time expense.
• Deficit Position: The company continues to operate with a substantial accumulated deficit of $1.37 billion affecting overall financial health and shareholder equity, which stood at $82.98 million as of June 30, 2025.

Key Financial Statistics:

• Q2 2025 Revenue: $10.74 million (up from $1.73 million in Q2 2024)
• Operating Expenses Q2 2025: $9.25 million (down from $23.31 million in Q2 2024)
• Net Income Q2 2025: $2.52 million (compared to a net loss of $19.80 million in Q2 2024)
• Cash, Cash Equivalents, and Marketable Securities: $98.1 million as of June 30, 2025
• Workforce Reduction: 57% reduction announced in March 2025
• Deficit Accumulated: $1.37 billion

The company is currently in extensive litigation regarding patent infringement against Moderna and Pfizer, both of which have implications for its technological assets, specifically in the area of mRNA delivery technology. Although they have settled some collaborations, the legal outcomes may significantly affect future revenue prospects. Arbutus is also currently focused on advancing its pipeline, especially imdusiran, potentially enhancing its position within the hepatitis B treatment market.

As the company continues to navigate its restructuring efforts and strategic partnerships, investors should closely monitor upcoming developments, particularly regarding the ongoing litigation and clinical trial progress for its therapeutic candidates.